Compile Data Set for Download or QSAR
Report error Found 302 Enz. Inhib. hit(s) with all data for entry = 9177
TargetPlasma kallikrein(Human)
Biocryst Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 416900BDBM416900(US10329260, Compound 56c | 1-(3-(aminomethyl)pheny...)
Affinity DataKi:  25.1nMAssay Description:The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates. In these experiments, 2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/22/2021
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Biocryst Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 416841BDBM416841(US10329260, Compound 51f | Racemic 1-(3-(aminometh...)
Affinity DataKi:  25.1nMAssay Description:The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates. In these experiments, 2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/22/2021
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Biocryst Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 416867BDBM416867(US10329260, Compound 53f | 1-(3-(aminomethyl)pheny...)
Affinity DataKi:  25.1nMAssay Description:The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates. In these experiments, 2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/22/2021
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Biocryst Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 416960BDBM416960(1-(3-(aminomethyl)phenyl)-N-(5-(3-cyclopropyl-1-(2...)
Affinity DataKi:  25.1nMAssay Description:The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates. In these experiments, 2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/22/2021
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Biocryst Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 416841BDBM416841(US10329260, Compound 51f | Racemic 1-(3-(aminometh...)
Affinity DataKi:  25.1nMAssay Description:The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates. In these experiments, 2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/22/2021
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Biocryst Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 416954BDBM416954(1-(3-(aminomethyl)phenyl)-N-(5-(3-cyclopropyl-1-(2...)
Affinity DataKi:  25.1nMAssay Description:The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates. In these experiments, 2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/22/2021
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Biocryst Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 416957BDBM416957((+-)-1-(1-aminoisoquinolin-7-yl)-N-(5-(3-cycloprop...)
Affinity DataKi:  25.1nMAssay Description:The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates. In these experiments, 2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/22/2021
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Biocryst Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 416900BDBM416900(US10329260, Compound 56c | 1-(3-(aminomethyl)pheny...)
Affinity DataKi:  25.1nMAssay Description:The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates. In these experiments, 2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/22/2021
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Biocryst Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 416894BDBM416894(US10329260, Compound 55b | 1-(3-(aminomethyl)pheny...)
Affinity DataKi:  25.1nMAssay Description:The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates. In these experiments, 2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/22/2021
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Biocryst Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 416894BDBM416894(US10329260, Compound 55b | 1-(3-(aminomethyl)pheny...)
Affinity DataKi:  25.1nMAssay Description:The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates. In these experiments, 2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/22/2021
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Biocryst Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 416794BDBM416794(US10329260, Compound 48f | Racemic 1-(3-(aminometh...)
Affinity DataKi:  25.1nMAssay Description:The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates. In these experiments, 2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/22/2021
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Biocryst Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 416906BDBM416906(US10329260, Compound 61e | 1-(3-(aminomethyl)pheny...)
Affinity DataKi:  25.1nMAssay Description:The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates. In these experiments, 2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/22/2021
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Biocryst Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 416751BDBM416751(US10329260, Compound 46g | Racemic 1-(3-(aminometh...)
Affinity DataKi:  25.1nMAssay Description:The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates. In these experiments, 2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/22/2021
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Biocryst Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 416794BDBM416794(US10329260, Compound 48f | Racemic 1-(3-(aminometh...)
Affinity DataKi:  25.1nMAssay Description:The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates. In these experiments, 2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/22/2021
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Biocryst Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 416948BDBM416948(1-(3-(aminomethyl)phenyl)-N-(5-(3-cyclopropyl-1-ph...)
Affinity DataKi:  25.1nMAssay Description:The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates. In these experiments, 2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/22/2021
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Biocryst Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 416975BDBM416975((+-)-N-(5-(1-amino-3-cyclopropyl-1-(pyridin-2-yl)p...)
Affinity DataKi:  25.1nMAssay Description:The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates. In these experiments, 2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/22/2021
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Biocryst Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 416974BDBM416974((+-)-1-(3-(aminomethyl)phenyl)-N-(5-(3-cyclopropyl...)
Affinity DataKi:  25.1nMAssay Description:The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates. In these experiments, 2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/22/2021
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Biocryst Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 416977BDBM416977((+-)-N-(5-(1-acetamido-3-cyclopropyl-1-(pyridin-3-...)
Affinity DataKi:  25.1nMAssay Description:The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates. In these experiments, 2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/22/2021
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Biocryst Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 416747BDBM416747(US10329260, Compound 34c | 1-(3-(Aminomethyl)pheny...)
Affinity DataKi:  25.1nMAssay Description:The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates. In these experiments, 2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/22/2021
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Biocryst Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 416837BDBM416837(US10329260, Compound 49h | 1-(3-(aminomethyl)pheny...)
Affinity DataKi:  25.1nMAssay Description:The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates. In these experiments, 2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/22/2021
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Biocryst Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 416973BDBM416973((+)-N5-(5-(1-amino-1-(4-cyanophenyl)-3-cyclopropyl...)
Affinity DataKi:  25.1nMAssay Description:The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates. In these experiments, 2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/22/2021
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Biocryst Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 416972BDBM416972((+-)-1-(3-(aminomethyl)phenyl)-N-(5-((bis(cyclopro...)
Affinity DataKi:  25.1nMAssay Description:The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates. In these experiments, 2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/22/2021
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Biocryst Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 416837BDBM416837(US10329260, Compound 49h | 1-(3-(aminomethyl)pheny...)
Affinity DataKi:  25.1nMAssay Description:The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates. In these experiments, 2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/22/2021
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Biocryst Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 416747BDBM416747(US10329260, Compound 34c | 1-(3-(Aminomethyl)pheny...)
Affinity DataKi:  25.1nMAssay Description:The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates. In these experiments, 2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/22/2021
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Biocryst Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 416856BDBM416856(US10329260, Compound 60e | 1-(3-(aminomethyl)pheny...)
Affinity DataKi:  25.1nMAssay Description:The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates. In these experiments, 2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/22/2021
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Biocryst Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 416856BDBM416856(US10329260, Compound 60e | 1-(3-(aminomethyl)pheny...)
Affinity DataKi:  25.1nMAssay Description:The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates. In these experiments, 2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/22/2021
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Biocryst Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 416867BDBM416867(US10329260, Compound 53f | 1-(3-(aminomethyl)pheny...)
Affinity DataKi:  25.1nMAssay Description:The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates. In these experiments, 2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/22/2021
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Biocryst Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 416991BDBM416991((+)-N-(3-(1-amino-1-(3-cyanophenyl)-3-cyclopropylp...)
Affinity DataKi:  25.1nMAssay Description:The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates. In these experiments, 2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/22/2021
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Biocryst Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 416987BDBM416987((+-)-N-(5-(1-amino-3-cyclopropyl-1-phenylpropyl)-2...)
Affinity DataKi:  25.1nMAssay Description:The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates. In these experiments, 2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/22/2021
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Biocryst Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 416993BDBM416993((+)-N-(5-(1-amino-1-(4-cyanophenyl)-3-cyclopropylp...)
Affinity DataKi:  25.1nMAssay Description:The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates. In these experiments, 2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/22/2021
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Biocryst Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 416992BDBM416992((+-)-1-(3-(aminomethyl)phenyl)-N-(5-(3-cyclopropyl...)
Affinity DataKi:  25.1nMAssay Description:The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates. In these experiments, 2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/22/2021
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Biocryst Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 416987BDBM416987((+-)-N-(5-(1-amino-3-cyclopropyl-1-phenylpropyl)-2...)
Affinity DataKi:  25.1nMAssay Description:The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates. In these experiments, 2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/22/2021
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Biocryst Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 416986BDBM416986((+-)-1-(3-(aminomethyl)phenyl)-N-(5-(3-cyclopropyl...)
Affinity DataKi:  25.1nMAssay Description:The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates. In these experiments, 2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/22/2021
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Biocryst Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 416989BDBM416989((+)-N-(5-(1-amino-3-cyclopropyl-1-(pyridin-4-yl)pr...)
Affinity DataKi:  25.1nMAssay Description:The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates. In these experiments, 2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/22/2021
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Biocryst Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 416988BDBM416988((+)-N-(3-(1-amino-1-(4-cyanophenyl)-3-cyclopropylp...)
Affinity DataKi:  25.1nMAssay Description:The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates. In these experiments, 2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/22/2021
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Biocryst Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 416983BDBM416983((+-)-1-(3-(aminomethyl)phenyl)-N-(5-(3-cyclopropyl...)
Affinity DataKi:  25.1nMAssay Description:The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates. In these experiments, 2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/22/2021
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Biocryst Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 439568BDBM439568(US10689346, Compound 235g | US10633345, Compound 2...)
Affinity DataKi:  25.1nMAssay Description:The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates. In these experiments, 2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/22/2021
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Biocryst Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 416981BDBM416981((+)-N-(5-(1-amino-3-cyclopropyl-1-(pyridin-3-yl)pr...)
Affinity DataKi:  25.1nMAssay Description:The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates. In these experiments, 2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/22/2021
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Biocryst Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 416979BDBM416979((+)-1-(3-(aminomethyl)phenyl)-5-(5-((cyclopropylme...)
Affinity DataKi:  25.1nMAssay Description:The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates. In these experiments, 2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/22/2021
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Biocryst Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 416975BDBM416975((+-)-N-(5-(1-amino-3-cyclopropyl-1-(pyridin-2-yl)p...)
Affinity DataKi:  25.1nMAssay Description:The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates. In these experiments, 2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/22/2021
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Biocryst Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 416981BDBM416981((+)-N-(5-(1-amino-3-cyclopropyl-1-(pyridin-3-yl)pr...)
Affinity DataKi:  25.1nMAssay Description:The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates. In these experiments, 2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/22/2021
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Biocryst Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 416980BDBM416980((+-)-1-(3-(aminomethyl)phenyl)-N-(5-(3-cyclopropyl...)
Affinity DataKi:  25.1nMAssay Description:The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates. In these experiments, 2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/22/2021
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Biocryst Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 417007BDBM417007((+)-N-(5-(1-amino-1-(3-cyanophenyl)-3-cyclopropylp...)
Affinity DataKi:  25.1nMAssay Description:The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates. In these experiments, 2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/22/2021
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Biocryst Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 417006BDBM417006((+)-N-(5-(1-amino-1-(3-cyanophenyl)-3-cyclopropylp...)
Affinity DataKi:  25.1nMAssay Description:The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates. In these experiments, 2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/22/2021
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Biocryst Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 417009BDBM417009(1-(3-carbamimidoylphenyl)-N-(5-((+-)-3-cyclopropyl...)
Affinity DataKi:  25.1nMAssay Description:The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates. In these experiments, 2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/22/2021
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Biocryst Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 417008BDBM417008((+)-N-(5-(1-amino-1-(6-cyanopyridin-2-yl)-3-cyclop...)
Affinity DataKi:  25.1nMAssay Description:The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates. In these experiments, 2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/22/2021
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Biocryst Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 417003BDBM417003((+)-1-(3-carbamimidoylphenyl)-N-(5-((3-cyanophenyl...)
Affinity DataKi:  25.1nMAssay Description:The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates. In these experiments, 2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/22/2021
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Biocryst Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 417004BDBM417004((+-)-1-(1-aminoisoquinolin-7-yl)-N-(5-((cyclopropy...)
Affinity DataKi:  25.1nMAssay Description:The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates. In these experiments, 2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/22/2021
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Biocryst Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 416993BDBM416993((+)-N-(5-(1-amino-1-(4-cyanophenyl)-3-cyclopropylp...)
Affinity DataKi:  25.1nMAssay Description:The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates. In these experiments, 2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/22/2021
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Biocryst Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 416998BDBM416998((+)-N-(5-(1-amino-1-(4-cyanophenyl)-3-cyclopropylp...)
Affinity DataKi:  25.1nMAssay Description:The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates. In these experiments, 2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/22/2021
Entry Details
US Patent

Displayed 1 to 50 (of 302 total ) | Next | Last >>
Jump to: